The number of colorectal cancer cases in people under 50 is rising worldwide, especially in high-income countries. Possible ...

A rare cell in the lining of lungs is fundamental to the organ-wide response necessary to repair damage from toxins like ...

Imatinib has also been assessed in patients with advanced phases of CML. In a Phase II study in patients with AP CML (n = 181; 34% newly diagnosed, 66% pretreated), imatinib 400 or 600 mg/day for ...

Objective To evaluate the performance of clinical criteria for predicting late treatment failure in patients with early non-response to certolizumab pegol (CZP).Methods A protocol-specified analysis ...

Asciminib shows superior tolerability over nilotinib in newly diagnosed CML-CP patients, reducing treatment discontinuation ...

Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers ...

According to the results, olverembatinib demonstrated high complete remission (CR) and complete molecular response (CMR) rates ... approved in China for the treatment of patients with CML in chronic ...

NEW YORK – Enliven Therapeutics on Friday priced a public offering of its common stock, expecting to bring in gross proceeds of around $200 million. In the underwritten offering, slated to close ...

A 14-gene molecular assay for the identification of high-risk patients with stage IA to IIA nonsquamous non–small cell lung cancer (NSCLC) most likely to derive benefit from adjuvant chemotherapy led ...